Filing summary
Entity note: The supplied filing is Flora Growth Corp.’s Form 10-Q, not a filing for Zerostack Corp. It covers the quarter and nine months ended September 30, 2023, and was signed November 8, 2023. Unaudited financial amounts below are in U.S. dollars.
Business context and reporting period
Flora manufactures and distributes consumer cannabis and wellness products and distributes pharmaceutical products. Its principal businesses include JustCBD, Vessel and Germany-based Phatebo. During the quarter, it continued to exit its Colombian operations, describing the sale as a strategic shift to focus on U.S. lifestyle brands and international pharmaceutical distribution. Results include FGH, acquired in December 2022, so year-over-year comparisons are affected by acquisition timing.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $17.3 million | $9.7 million | $58.1 million | $22.9 million |
| Gross profit / margin | $4.9 million / 29% | $4.7 million / 48% | $14.2 million / 25% | $10.2 million / 45% |
| Operating loss | $0.5 million | $4.4 million | $43.0 million | $32.2 million |
| Net income (loss) | $1.1 million | $(7.4) million | $(47.3) million | $(39.7) million |
| Cash from (used in) operating activities | $0.5 million | $(4.0) million | $(7.3) million | $(15.0) million |
| Adjusted EBITDA, non-GAAP | $(0.2) million | $(3.6) million | $(4.9) million | $(9.6) million |
At September 30, cash and restricted cash totaled $4.8 million; working capital was $7.3 million. Total assets were $31.6 million and total liabilities were $18.5 million. Current debt was $1.1 million, principally a €1.0 million Phatebo credit facility; lease liabilities totaled $2.0 million. The company also reported $5.4 million of contingencies, including legal and sales-tax provisions.
Material changes versus comparable periods
- Quarterly revenue rose 78% year over year, primarily because FGH contributed $9.0 million; JustCBD revenue declined to $6.5 million from $7.8 million. Nine-month revenue growth also reflected acquisition contributions from FGH and JustCBD.
- Gross margin contracted sharply, which management attributed mainly to FGH’s lower-margin pharmaceutical distribution business. Q3 gross profit increased only modestly despite higher revenue.
- Q3 operating expenses fell to $5.5 million from $9.1 million, reflecting cost reductions, including lower corporate headcount and marketing-related expenses. Q3 operating cash flow turned positive; management said it was the first quarter in which gross profit exceeded operating expenditures.
- Nine-month results included $34.9 million of continuing-operations impairment charges, including goodwill and long-lived asset impairments. Goodwill was fully impaired by September 30. The company reported a $47.3 million nine-month net loss, wider than the prior-year $39.7 million loss.
- Cash declined from $8.9 million at year-end 2022 to $4.8 million. A September registered direct offering generated $2.7 million gross proceeds through 1.369 million units, each including a share and a warrant; offering costs reduced proceeds.
Outlook, risks, contingencies and unusual items
- Going concern: Management stated that available cash was insufficient to fund growth and meet obligations as they come due, and that substantial doubt existed about the company’s ability to continue as a going concern for at least one year after issuance. Management is evaluating cost reductions and potential equity, debt, strategic-partner or other financing; availability and terms are not assured. The filing gives no quantified revenue or earnings guidance.
- Colombia divestiture: The sale was agreed for CAD $0.8 million (about $0.6 million). Proceeds of CAD $0.5 million had been received by quarter-end; the remaining Cosechemos Ya sale closed November 1, 2023. The nine-month discontinued-operations loss was $7.8 million, including impairment and disposal effects; Q3 discontinued-operations income of $0.5 million included a disposal-related accounting gain.
- Acquisition impairment and fair value: Impairment testing used management estimates, including discounted cash-flow assumptions. Fair-value changes on contingent purchase consideration produced a $2.2 million nine-month gain, contributing to non-operating income; such gains are not operating cash generation.
- Legal and tax exposures: The company recorded approximately $3.0 million for a German legal claim it considers without merit but assessed as a probable, estimable loss; it says the claim is covered by an indemnity, subject to a $5.0 million cap. It also provided $2.4 million for estimated U.S. sales taxes. Other share-claim lawsuits were described as disputed, with no accrual because management viewed an unfavorable outcome as remote.
- Subsequent transaction dispute: Lifeist delivered a notice purporting to terminate the agreement to sell Australian Vaporizers for 600,676 Flora shares. Flora disputes the purported termination and intends to contest it. The transaction had not closed as of the filing discussion.
- Share structure and listing: A 1-for-20 reverse split took effect June 9, 2023; the filing states Nasdaq notified the company it had regained minimum-bid-price compliance. The September offering and repriced warrants create potential dilution. The company reported 8,208,595 common shares outstanding on November 3, 2023.
Important facts for investors to verify
- Whether Flora obtains sufficient financing to address the expressly disclosed going-concern uncertainty, and its cash runway and near-term obligations.
- Whether Q3 positive operating cash flow is repeatable, given nine-month operating cash use and continued negative adjusted EBITDA.
- How much of revenue growth and future profitability depends on FGH, and whether margins can recover after the reported decline.
- The valuation assumptions and cash implications of impairment charges, contingent consideration, inventory, and aged receivables; trade receivables included $1.1 million more than 180 days past due.
- The final proceeds, remaining obligations and operating effects of the Colombia sale, and the outcome of the Australian Vaporizers contract dispute.
- The resolution and collectability of the FGH indemnity, the German claim, sales-tax provision and other litigation, as well as potential dilution from outstanding warrants.